摘要
目的 研究葡萄球菌肠毒素B(SEB)突变体的免疫原性和作为超抗原疫苗的应用前景。方法 利用小鼠动物模型 ,分别对SEB 2 3位突变体 (SEB -M2 3)和 15 0位突变体 (SEB -M 15 0 )作毒力、免疫原性和保护力试验。结果 小鼠致死性试验表明 ,与野生型SEB (SEB -N)相比 ,SEB -M 2 3的毒力大幅度下降 ,而SEB -M15 0的毒力则未见下降。淋巴细胞增殖试验发现 ,SEB -M15 0与SEB -N相比 ,cpm掺入量相似 ,说明 15 0位突变并不影响SEB超抗原的活性 ;SEB -M2 3与SEB -N相比 ,其cpm掺入量显著下降 ,表明 2 3位突变可显著降低SEB超抗原活性。ELISA结果显示 ,以SEB -N、SEB -M 2 3、SEB-M 15 0三种蛋白免疫小鼠 ,都能诱生一定量的抗体 ,且产生的抗体水平非常接近 ,无统计学意义。主动免疫治疗和被动免疫治疗结果证明 ,SEB -M2 3蛋白免疫的小鼠能抵抗野生型SEB致死剂量的攻击 ,同时被动转移免疫小鼠的抗血清能保护接受致死剂量SEB -N的小鼠免于死亡。结论 SEB -M 2 3毒力低、免疫原性强 ,有可能成为一种很有希望的超抗原候选疫苗 ,用于某些疾病的预防。
Aim To study the immunogenicity of staphylococcal enterotoxin B (SEB) mutants and the feasibility of superantigen vaccine.Methods Animal model was used to evaluate the virulence,immunogenicity and protective effect of SEB mutant at the residue 23 (SEB-M23) and SEB mutant at the residue 150(SEB-M150).Results Mouse lethality assay and lymphocyte proliferation test indicated that compared with wild type SEB(SEB-N),the virulence and superantigen toxicity of SEB-M23 mutant decreased sharply while the virulence and superantigen toxicity of SEB-M150 mutant showed no marked difference.Enzyme-linked immunosorbent assay manifested that immunized mice with these three proteins produced very similar anti-SEB titers.The results of active and passive immunization therapy demonstrated that SEB-M23-immunized mice could resist SEB-N lethal challenge and mice were completely protected from SEB lethality by antisera from SEB-M23-immunized mice.Conclusion Since SEB-M23 showed normal antigenicity but low toxicity,it is a promising superantigen vaccine.
出处
《中国人兽共患病杂志》
CSCD
北大核心
2003年第6期42-44,34,共4页
Chinese Journal of Zoonoses
